Drugs / TEV-50717
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT03452943 | Feb 2018 → Nov 2019 | Tourette syndrome | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Missed primary |
| Phase 34 trials · 2 missed | ||||||
| Phase 3 | NCT04200352 | Feb 2020 → Feb 2023 | athetoid cerebral palsy | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03813238 | Aug 2019 → Jul 2022 | athetoid cerebral palsy | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Missed primary |
| Phase 3 | NCT03571256 | May 2018 → Dec 2019 | Tourette syndrome | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Missed primary |
| Phase 3 | NCT03567291 | May 2018 → May 2020 | Tourette syndrome | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEV-50717 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03571256 ↗ |
| Route | Oral | “6, 9, and 12 mg oral tablets” NCT03567291 ↗ |